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of Cardiovascular Events and Death
in Diabetic Patients With Angiographically
Proven Asymptomatic Coronary Artery Disease
A Potential Protective Role
for Statins and 5-Phosphodiesterase Inhibitors
Carmine Gazzaruso, MD, PHD,* Sebastiano B. Solerte, MD,† Arturo Pujia, MD,§
Adriana Coppola, RN, MS,* Monia Vezzoli, MD,* Fabrizio Salvucci, MD,* Cinzia Valenti, MD,*
Andrea Giustina, MD, Adriana Garzaniti, MD‡
Vigevano, Pavia, Catanzaro, and Brescia, Italy
Objectives We sought to investigate whether erectile dysfunction (ED) is a predictor of future cardiovascular events and
death in diabetic patients with silent coronary artery disease (CAD) and whether there are predictors of cardio-
vascular events and death among CAD diabetic patients with ED.
Background Case-control studies showed that ED is associated with CAD in diabetic patients, but no prospective study is available.
Methods Type 2 diabetic men (n  291) with silent CAD angiographically documented were recruited. Erectile dysfunction
was assessed by the International Index Erectile Function-5 questionnaire.
Results During a follow-up period of 47.2  21.8 months (range 4 to 82 months), 49 patients experienced major ad-
verse cardiac events (MACE). The difference in ED prevalence between patients with and those without MACE
was significant (61.2% vs. 36.4%; p  0.001). Cox regression analysis showed that ED predicted MACE (hazard
ratio [HR] 2.1; 95% confidence interval [CI] 1.6 to 2.6; p  0.001). Among patients with CAD and ED, the
Kaplan-Meier method showed that the statin (Mantel log-rank test: 3.921; p  0.048) and 5-phosphodiesterase
(5-PDE) inhibitor use (Mantel log-rank test: 4.608; p  0.032) were associated with a lower rate of MACE. Cox
regression analysis showed that statin use (HR 0.66; 95% CI 0.46 to 0.97; p  0.036) reduced MACE. Treat-
ment with 5-PDE inhibitors did not enter the model, but its p value was very near to the significant level
(HR 0.68; 95% CI 0.46 to 1.01; p  0.056).
Conclusions Our data first show that ED is a powerful predictor of cardiovascular morbidity and mortality in diabetic patients with
silent CAD and that the treatment with statins and 5-PDE inhibitors might reduce the occurrence of MACE among
CAD diabetic patients with ED. (J Am Coll Cardiol 2008;51:2040–4) © 2008 by the American College of Cardiology
Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2007.10.069b
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teveral epidemiological studies showed that erectile dys-
unction (ED) is associated with coronary artery disease
CAD) in both diabetic and nondiabetic subjects (1–3).
nly 1 longitudinal report documented an association
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Manuscript received June 18, 2007; revised manuscript received October 9, 2007,
ccepted October 15, 2007.etween ED and CAD in the general population: in the
lacebo arm of the Prostate Cancer Prevention Trial,
hompson et al. (4) observed that prevalent and incident
D preceded coronary events. No prospective study is
See page 2051
vailable in diabetic patients. We aimed at assessing
hether ED is a predictor of cardiovascular events and
eath in diabetic patients with silent CAD and whether
here are predictors of cardiovascular morbidity and mortal-
ty in CAD diabetic patients with ED.
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total of 317 consecutive male type 2 diabetic patients with
ype 1 silent CAD (according to Braunwald) angiographically
ocumented were enrolled between November 1998 and
ebruary 2006. Some of the patients (97 subjects) were the
ame as in our previous report (3). The study population
ncluded patients who were diagnosed with silent CAD
ccording to the American Diabetes Association (ADA)
uidelines (5). An exercise stress testing was performed in
iabetic patients with conditions and/or risk factors sug-
ested by the aforementioned guidelines (5). In patients
ith any condition that did not permit maximal exercise
esting (such as severe obesity, foot wound, and so on) a
ipyridamole stress testing was performed. When an exer-
ise electrocardiogram (ECG) test was highly positive, the
uspicion of CAD was considered strong. In patients with a
ositive exercise ECG test, exercise stress thallium scintig-
aphy was performed. Procedures for stress testing and
cintigraphy and criteria to consider stress testing as positive
r highly positive were reported elsewhere (6,7). In patients
ith a highly positive exercise ECG or a positive scintigra-
hy or a positive dipyridamole stress testing, a diagnostic
oronary angiography was recommended. Angiography was
erformed as previously described (2). A coronary lesion was
onsidered significant when a stenosis 50% of the lumen
as documented. We used the same exclusion criteria as
eported in our previous studies (3,6,7). The study was
pproved by the ethics committee. All patients gave their
nformed consent both to perform each test and to partic-
pate in the study.
As in our previous studies (2,3,6,7), diabetes was diag-
osed according to ADA criteria and hypertension was
iagnosed according to European Society of Hypertension/
uropean Society of Cardiology criteria. Patients with
lbumin excretion rate (AER)30 mg/day were considered
ormoalbuminuric; patients with an albumin excretion rate
etween 30 and 299 mg/day were considered microalbu-
inuric. Patients were considered smokers if current smok-
rs or ex-smokers. A family history of CAD was considered
ositive in the presence of a documented myocardial isch-
mia or infarction in a first-degree relative. Body mass index
as calculated by the following formula: kg/m2. Autonomic
unction was assessed as previously reported (7).
Venous blood samples were taken from subjects after
asting for 12 h. Cholesterol, high-density lipoprotein
holesterol, and triglycerides were measured by an auto-
atic analyzer HITACHI 737 (Tokyo, Japan). High-
ensity lipoprotein cholesterol was calculated by the Friede-
ald’s formula. Glycated hemoglobin (HbA1c) was measured
y high-performance liquid chromatography (HPLC) (Bio-
ad, Richmond, California). The albumin excretion rate was
easured by nephelometry (Beckmann, Milan, Italy).
D assessment. Presence and degree of ED were assessed
y the validated International Index Erectile Function-5
IIEF-5) questionnaire (8). Erectile dysfunction was con- videred present when the IIEF-5
core was 21 (8). Only patients
ho filled in the questionnaire in
he year before the detection of
AD were enrolled.
ollow-up. Among 317 pa-
ients, 15 (4.7%) were lost at
ollow-up and 11 (3.5%) were
xcluded from the study because
hey had restenosis after percuta-
eous transluminal coronary an-
ioplasty within 6 months. Of
he 15 patients lost at follow-up,
had ED, whereas 7 of the 11
atients excluded from the study
ad ED. So, 291 patients with
omplete follow-up data were included in the study. The
AD was treated as judged appropriate by the cardiologists
n the basis of angiographic CAD severity. Of 291 patients,
76 underwent coronary bypass, 48 coronary angioplasty,
nd 67 were treated with pharmacological therapy alone.
ollow-up included periodic control visits in the outpatient
iabetes clinic (every 3 to 4 months) and in the outpatient
ardiology unit (every 6 to 12 months). At the beginning
nd during the follow-up, all patients were treated aggres-
ively with the purpose of reducing every cardiovascular risk
actor according to the current guidelines. So, appropriate
ifestyle changes were suggested and pharmacological treat-
ents, including statins, antihypertensive and antidiabetic
rugs, antiplatelet agents, and antianginal drugs, were pre-
cribed. In particular, according to current guidelines, most
atients were treated at baseline with angiotensin-converting
nzyme inhibitors and/or angiotensin-receptor blockers
84.5%) and statins (61.5%). These percentages did not
hange significantly during the follow-up.
The end point was the occurrence of major adverse cardiac
vents (MACE). The following were considered to be
ACE: CAD death, sudden death, nonfatal myocardial
nfarction, death due to congestive heart failure, unstable
ngina, need for repeat revascularization (aside from resteno-
is), stroke or transient ischemic attack (TIA), and symptom-
tic peripheral artery disease (PAD) documented by angiogra-
hy. Myocardial infarction was diagnosed on the basis of
linical symptoms, ECG changes, and cardiac enzyme eleva-
ions. Unstable angina was defined as a hospital stay because of
n episode of prolonged chest pain at rest associated with
schemic changes but no rise in biomarkers. Transient ischemic
ttack was defined by physician diagnosis of any sudden focal
eurological deficit that cleared definitively within 24 h.
Any information regarding potential MACE was vali-
ated by source data, including hospital record forms, death
ertificates, and other documents. Periodic contacts with
eneral practitioner and telephone interviews were under-
aken to evaluate the occurrence of MACE.
tatistical analysis. We assessed differences in normal
Abbreviations
and Acronyms
5-PDE 
5-phosphodiesterase
CAD  coronary artery
disease
CI  confidence interval
ECG  electrocardiogram
ED  erectile dysfunction
HR  hazard ratio
IIEF-5  International Index
Erectile Function-5
MACE  major adverse
cardiac eventsariables by the Student t test and differences in non-normal
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quare test was used for frequency comparison. Survival curves
ere estimated by the Kaplan-Meier test and compared by the
antel log-rank test. The effect of several variables on the
ccurrence of MACE was tested by the stepwise Cox regres-
ion analysis. Before the analysis, lipid parameters were ad-
usted for body mass index, smoking, statin use, presence of
ypertension, and microalbuminuria by an analysis of covari-
nce. The following variables were tested: age, diabetes dura-
ion, hypertension, family history of CAD, smoking, mi-
roalbuminuria, glycated hemoglobin, body mass index,
holesterol, triglycerides, low-density lipoprotein cholesterol,
igh-density lipoprotein cholesterol, ED, and autonomic dys-
unction. Variables were dichotomized as previously reported
3). Hazard ratios (HR) with a 95% confidence interval (CI)
ere computed to identify significant predictors of MACE. A
value 0.05 was considered statistically significant.
esults
able 1 shows the features of the whole study population at
aseline and of the patients stratified by the presence/
bsence of ED and MACE.
iological and Clinical Features of the Whole Study Population WitAD at Baseline, of Pati n s With and ithout ED, and of Patients
Table 1 Biological and Clinical Features of the Whole Study PoCAD at Baseline, of Patients With and Without ED, an
All ED
n 291 118 1
Age (yrs) 54.8 7.3 54.2 7.2 55
Duration of diabetes (yrs) 8.2 5.8 9.4 5.5 7
BMI 27.5 3.9 27.6 4.5 27
HbA1c (%) 7.3 1.1 7.3 1.0 7
Cholesterol (mg/dl) 209.6 29.1 209.7 27.3 209
LDL (mg/dl) 134.5 28.0 134.0 26.3 134
HDL (mg/dl) 43.6 9.5 43.9 8.3 43
Triglycerides (mg/dl) 157.0 57.5 158.8 56.2 155
Multivessel disease (%) 43.6 38.1
Bivessel disease (%) 32.6 38.1
Monovessel disease (%) 23.7 23.8
Microalbuminuria (%) 55.7 72.8
Smokers (%) 65.3 67.8
Family history of CAD (%) 44.7 44.1
Hypertension (%) 59.1 63.6
Autonomic neuropathy (%) 17.2 24.6
ED (%) 40.5 100
Total MACE (%) 14.3 25.4
MACE distribution (n)
Total events and deaths 49 30
CAD deaths 3 1
Sudden deaths 2 1
Nonfatal MI 14 8
Deaths due to CHF 1 1
Unstable angina 8 6
Repeat revascularization 3 2
Stroke or TIA 16 10
Peripheral artery disease 2 1Erectile dysfunction (ED) versus no ED. †Major adverse cardiac events (MACE) versus no MACE.
BMI  body mass index; CAD  coronary artery disease; CHF  congestive heart failure; HbA1c  glyccurrence of MACE. The follow-up period duration
as defined as the period of time up to the occurrence of
he first MACE or up to the last information obtained.
ean follow-up period was 47.2  21.8 months (range 4
o 82 months). During the follow-up period 49 patients
ad MACE: Table 1 reports MACE distribution. Pa-
ients with ED experienced a significantly greater inci-
ence of MACE as compared with patients without ED.
otential impact of pharmacological treatment on the
ccurrence of MACE. The potential impact of several
lasses of drugs on the occurrence of MACE was evalu-
ted. In particular, no difference in the percentage of
atients treated with angiotensin-converting enzyme in-
ibitors, angiotensin-receptor blockers, beta-blockers,
nsulin, diabetes oral agents, diuretics, calcium-channel
lockers, or platelet antiaggregants at baseline was found
etween patients with and without ED or between
atients with and without MACE (data not shown). No
ifference in the percentage of patients treated with
tatins was observed between patients with and without
D (60.2% vs. 62.4%; p  0.697). Nevertheless, the
ercentages of patients treated with statins was signifi-
ntand Without MACE
ion With Silent
atients With and Without MACE
p Value* MACE No MACE p Value†
49 242
.4 0.307 54.5 7.7 54.8 7.2 0.764
.8 0.003 7.6 5.1 8.3 5.9 0.454
.5 0.581 27.4 4.2 27.5 3.8 0.936
.2 0.584 7.6 1.0 7.2 1.1 0.069
0.3 0.953 211.5 28.6 209.2 29.2 0.615
9.2 0.799 138.6 25.5 133.7 28.5 0.262
0.2 0.689 43.2 10.4 43.7 9.3 0.706
8.5 0.660 148.4 54.2 158.8 58.1 0.251
40.8 44.2
0.200 30.6 33.0 0.680
28.6 22.8
0.001 85.7 49.6 0.001
0.458 65.3 65.3 0.998
0.863 46.9 44.2 0.726
0.202 61.2 58.7 0.740
0.005 36.7 13.2 0.001
61.2 36.4 0.001
0.001 100 0
49 0
3 0
2 0
14 0
1 0
8 0
3 0
16 0
2 0h SileWith
pulat
d of P
No ED
73
.1 7
.3 5
.4 3
.3 1
.4 3
.9 2
.4 1
.8 5
47.4
28.9
23.7
43.9
63.6
45.1
56.1
12.1
0
11.0
19
2
1
6
0
2
1
6
1cated hemoglobin; TIA  transient ischemic attack.
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ACE (40.8% vs. 65.7%; p  0.001).
ultivariate analysis. The Kaplan-Meier method showed
hat ED was associated with a higher rate of MACE
log-rank test: 41.847; p  0.001) (Fig. 1). Univariate
ogistic regression showed an association between ED and
ACE: HR 2.8; 95% CI 1.5 to 5.2; p  0.002. A
ultivariate Cox regression analysis showed that ED was
he only predictor of MACE: HR 2.1; 95% CI 1.6 to 2.6;
 0.001.
ubgroup analysis. To identify possible predictors of
ACE in ED patients, the analysis of this subgroup was
erformed. Table 2 shows features of ED patients with and
ithout MACE. Also in this subgroup, the potential impact
f the aforementioned classes of drugs on the reported
ccurrence of MACE was evaluated, but no difference was
ound between patients with and without MACE. The
ercentage of patients treated with statins was significantly
ower among ED patients with than among those without
ACE (33.3% vs. 69.3%; p  0.0005). Among the 118
D patients, 37.3% were treated with 5-phosphodiesterase
5-PDE) inhibitors at baseline. Interestingly, the percentage
f ED patients treated with 5-PDE inhibitors was signifi-
antly lower among patients with than among those without
ACE (20.0% vs. 43.2%; p  0.0234).
The Kaplan-Meier method showed that, among ED
atients, microalbuminuria (log-rank test: 6.087; p 0.014)
as associated with a higher rate of MACE, whereas statin
log-rank test: 3.921; p  0.048) and 5-PDE inhibitor use
log-rank test: 4.608; p  0.032) were associated with a
ower rate of MACE. Figure 2 shows the Kaplan-Meier
Figure 1 Kaplan-Meier Analysis in Diabetic
Patients With Silent Coronary Artery Disease
Event-free survival estimate according to
presence/absence of erectile dysfunction (ED).urve according to 5-PDE inhibitor use. Univariate logistic
egression showed an association of MACE with statin
HR 0.2; 95% CI 0.1 to 0.5; p  0.001) and 5-PDE
nhibitor use (HR 0.3; 95% CI 0.1 to 0.9; p  0.028).
A Cox regression analysis showed that predictors of
ACE were microalbuminuria (HR 1.56; 95% CI 1.02 to
.36; p  0.036) and statin use (HR 0.66; 95% CI 0.46 to
.97; p  0.036); 5-PDE inhibitor use did not enter the
iological and Clinical Features ofD Patients With and Without MACE
Table 2 Biological and Clinical Features ofED Patients With and Without MACE
MACE No MACE p Value
n 30 88
Age (yrs) 54.5 7.7 54.2 7.0 0.823
Duration of diabetes (yrs) 8.0 5.3 9.8 5.6 0.131
BMI 27.7 4.7 27.6 4.4 0.934
HbA1c (%) 7.2 1.0 7.4 1.1 0.659
Cholesterol (mg/dl) 210.2 30.0 209.5 26.5 0.916
LDL (mg/dl) 136.4 24.6 133.2 27.0 0.574
HDL (mg/dl) 42.6 9.5 44.3 7.9 0.352
Triglycerides (mg/dl) 155.5 57.8 159.9 55.9 0.711
Multivessel disease (%) 40.0 37.5
Bivessel disease (%) 26.7 37.0 0.224
Monovessel disease (%) 33.3 20.5
Microalbuminuria (%) 90.0 67.1 0.015
Smokers (%) 66.7 68.2 0.878
Family history of CAD (%) 46.7 43.2 0.739
Hypertension (%) 70.0 61.4 0.396
Autonomic neuropathy (%) 46.7 17.1 0.001
Total MACE (%) 100 0
DL  high-density lipoprotein cholesterol; LDL  low-density lipoprotein cholesterol; other
bbreviations as in Table 1.
Figure 2 Kaplan-Meier Analysis in Diabetic
Patients With Silent CAD and ED
Event-free survival estimate according to the use of 5-phosphodiesterase
(5-PDE) inhibitors. CAD  coronary artery disease; ED  erectile dysfunction.
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HR 0.68; 95% CI 0.46 to 1.01; p  0.056).
iscussion
o study investigated the impact of ED on cardiovascular
orbidity and mortality in a population at very high
ardiovascular risk with a high prevalence of ED like
iabetic patients with CAD. The finding that ED is a
owerful predictor of MACE in our population might be of
linical interest. Indeed, our study suggests that, although
ll diabetic patients are at high cardiovascular risk, those
ith ED might be at particularly very high risk. This might
mply that, in diabetic patients with ED, specific and
ggressive programs to prevent cardiovascular events should
e performed. Thus it is intriguing to understand how to
educe the cardiovascular risk in ED patients. We found
hat the use of statins could protect against the occurrence of
ACE in ED patients. This might owe both to high-
ensity lipoprotein cholesterol reduction and to the so-
alled pleiotropic effects attributed to statins (9). Among
hese pleiotropic effects there is the improvement in endo-
helial dysfunction (9), which seems to be the link between
D and atherothrombosis (1).
Another original finding is that PDE-5 inhibitors might
rotect against the development of MACE in CAD dia-
etic patients with ED. Both Kaplan-Meier and univariate
nalysis show an association between PDE-5 inhibitor use
nd lower risk of MACE, although in multivariate analysis
DE-5 inhibitor use does not attain statistical significance.
he relatively small subgroup of ED patients and the fact
hat our study is not interventional might explain this result,
ven if the p value was very near to the significance level.
nyway, PDE-5 inhibitors might really reduce the cardio-
ascular risk for several reasons. Indeed, these drugs were
orn as antianginals, and they are able to improve endothe-
ial dysfunction (10,11). Furthermore, recent studies dem-
nstrated that 5-PDE inhibitors can have several cardiopro-
ective effects and they seem to provide potential
athophysiological mechanisms by which these drugs might
educe the cardiovascular risk (10,11). So, our findings could
ot be surprising and, if confirmed by specific intervention
tudies, they might imply that in patients with stable CAD
DE-5 inhibitors not only are not contraindicated butight even play a major role in the prevention of cardio-
ascular events.
onclusions
n conclusion, our study shows that ED is a powerful
redictor of MACE in diabetic patients at very high
ardiovascular risk, namely with CAD angiographically
roven. Additional studies should confirm our findings in
ther populations. Among diabetic patients with silent
AD and ED, statins and PDE-5 inhibitors might reduce
ardiovascular morbidity and mortality.
eprint requests and correspondence: Dr. Carmine Gazzaruso,
linical Institute “Beato Matteo,” Via Aselli, 5, 27100 Pavia, Italy.
-mail: c.gazzaruso@tele2.it.
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